AdAlta secures licensing deal with GE Healthcare
Filed with ASX · · 2 pages · English
Earlier from AdAlta
- Executive team changes
- GLP toxicology study commences
- Entitlement Offer Results and Shortfall Notification
- Completion of Capital Raise - $5 million
- AD-214 manufacturing update
Later from AdAlta
- Receipt of R&D Tax Incentive
- Tim Oldham Appointed as Chief Executive Officer
- GLP Toxicology study results
- AdAlta awarded Biomedical Translation Bridge Funding
- AD-214 Phase I strategy and timing update
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta